Literature DB >> 11812704

The effects of intravenous anesthetics and lidocaine on proliferation of cultured type II pneumocytes and lung fibroblasts.

Kahoru Nishina1, Katsuya Mikawa, Osamu Morikawa, Hidefumi Obara, R J Mason.   

Abstract

UNLABELLED: Type II pneumocytes synthesize surfactant and differentiate into type I pneumocytes to maintain the epithelium (1). Alveolar type II cell proliferation is required for reepithelization after acute lung injury (ALI) and is thought to minimize the subsequent fibrotic response (1). Keratinocyte growth factor (KGF) and hepatocyte growth factor (HGF) are among the most potent mitogen for type II epithelial cells, but not for fibroblasts in the lung (1). These growth factors attenuate several experimental ALI models by promoting epithelial repair (2,3). Thus, KGF and HGF may be a promising therapeutic approach to ALI. Critically ill patients with ALI often receive IV anesthetics or sedatives to facilitate mechanical ventilation. Furthermore, these patients sometimes undergo bronchoscopy under local anesthesia to obtain bronchoalveolar lavage fluid or to remove respiratory secretions. Several IV and local anesthetics inhibit proliferation of various cells including epithelium (4,5). If these anesthetics impede proliferation of type II pneumocytes, this suppressive effect may be a disadvantage for alveolar reepithelization in the course of recovery from ALI. In this study, we examined the effects of midazolam, propofol, ketamine, thiopental, and lidocaine on proliferation of type II alveolar epithelial cells using in vitro culture system. Because fibroblast proliferation is a key event in late phase of ALI, inhibition of this fibroproliferation is probably beneficial. Thus, we further determined whether these anesthetics could regulate proliferation of lung fibroblasts. In the current study, rolipram was used as a positive control. In our previous preliminary experiment, we found that rolipram, a phosphodiesterase inhibitor type IV, augments spontaneous or KGF-/HGF-promoted type II cell proliferation (6). IMPLICATIONS: Midazolam, ketamine, thiopental, propofol, or lidocaine did not inhibit proliferation of cultured rat type II pneumocytes. Our findings suggest that these anesthetics do not impede alveolar reepithelization after acute lung injury.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11812704     DOI: 10.1097/00000539-200202000-00029

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  5 in total

1.  In vitro exposure of human fibroblasts to local anaesthetics impairs cell growth.

Authors:  C Fedder; B Beck-Schimmer; J Aguirre; M Hasler; B Roth-Z'graggen; M Urner; S Kalberer; A Schlicker; G Votta-Velis; J M Bonvini; K Graetz; A Borgeat
Journal:  Clin Exp Immunol       Date:  2010-09-01       Impact factor: 4.330

2.  The effects of intravenous anesthetics on mouse embryonic fibroblast viability and proliferation.

Authors:  Yoon Ji Choi; Se Keun Jeon; Jungjoo Kim; Yongdoo Park; Seung Zhoo Yoon; Kyung Sun
Journal:  J Anesth       Date:  2012-06-20       Impact factor: 2.078

3.  Balance of life and death in alveolar epithelial type II cells: proliferation, apoptosis, and the effects of cyclic stretch on wound healing.

Authors:  Lynn M Crosby; Charlean Luellen; Zhihong Zhang; Larry L Tague; Scott E Sinclair; Christopher M Waters
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-07-01       Impact factor: 5.464

Review 4.  Effects of Anesthetics on Barrier Tissue Function.

Authors:  Fujing Wang; Yanhui Li; Changlei Cui; Zhaoping Xue; Haichun Ma
Journal:  J Immunol Res       Date:  2019-10-21       Impact factor: 4.818

5.  Effect of Lignocaine Concentration on Human Fibroblasts Growth in Eyes Undergoing Trabeculectomy: An in vitro Study.

Authors:  Madhuravasal Krishnan Janani; Venkatakrishnan Jaichandran; Hajib Narahari Rao Madhavan; Lingam Vijaya; Ronnie Jacob George; Priyam Shrikant Ambastha; Abhijeet Manu; Jambulingam Malathi
Journal:  Biomed Hub       Date:  2018-10-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.